Side-by-side · Research reference

GHK-CuvsLiraglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticReviewed8/47 cited

BFDA-ApprovedVerified14/45 cited

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

01Mechanism of Action

Parameter

GHK-Cu

Liraglutide

Primary target

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Pathway

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Downstream effect

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Feedback intact?

Replaces declining endogenous levels

Glucose-dependent insulin release preserves physiological feedback

Origin

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Antibody development

—

02Dosage Protocols

Parameter

GHK-Cu

Liraglutide

Standard SQ dose

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

—

Topical concentration

0.1–2.0% in serum / cream

—

Frequency

Daily or 2–3× per week (SQ)

Once daily, same time each day

Lower / starter dose

0.5 mg / day SQ

—

Evidence basis

Human-mechanistic + topical clinical studiesPickart 2018

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Duration

8–12 weeks for visible skin / hair effect

Indefinite for chronic indication

Reconstitution

Bacteriostatic water; light-protected

Pre-filled commercial pen (no reconstitution)

Timing

No specific time; evening preferred for topicals

Any time of day; consistent

Half-life

Hours (estimated; rapid tissue uptake)

~13 hrSAXENDA (liraglutide) injectio 2014

Standard dose (T2D, Victoza)

—

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

Standard dose (weight, Saxenda)

—

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

Titration schedule

—

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

04Side Effects & Safety

Parameter

GHK-Cu

Liraglutide

Injection site reaction

Erythema, mild pruritus (common)

—

Topical irritation

Mild redness, transient stinging

—

Copper accumulation

Theoretical with very high chronic doses

—

Allergic reaction

Rare hypersensitivity to copper

—

Pregnancy / OB

Avoid topical and SQ — insufficient data

Contraindicated

Wilson disease

Contraindicated

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

Pancreatitis risk

—

Rare; discontinue if suspected

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

Hypoglycemia

—

Low risk as monotherapy; elevated with sulfonylureas / insulin

Heart rate

—

Modest ↑ resting HR (~2-3 bpm)

Cardiovascular benefit

—

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

Absolute Contraindications

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Relative Contraindications

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

05Administration Protocol

Parameter

GHK-Cu

Liraglutide

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

Commercial pre-filled pen, no reconstitution required.

2. Injection site

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Anytime; evening preferred. Topical: apply to clean dry skin.

Once daily, same time each day. Take with or without food.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

5. Needle

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

Pen-supplied 32G needle.

06Stack Synergy

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair

Liraglutide

— no documented stacks